RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

Cell and gene ther­a­py CD­MO RoslinCT will keep man­u­fac­tur­ing Ver­tex and CRISPR Ther­a­peu­tics’ CRISPR gene edit­ing ther­a­py exa-cel — this time for com­mer­cial use.

Exa-cel, now mar­ket­ed as Cas­gevy, was au­tho­rized in the UK for sick­le cell dis­ease and trans­fu­sion-de­pen­dent be­ta-tha­lassemia on Nov. 16. This is the first time any CRISPR-based ap­proach has been ap­proved, which al­so means that the Scot­tish CD­MO will al­so be the first to man­u­fac­ture the prod­uct for use out­side clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER